UPDATE: Roth On GlycoMimetics: Firm Sees 1st Patient Dosed With Uproleselan In An Investigator-Sponsored Trial; Strong Data Supports Upro E-selectin Antagonist In Combo With Chemotherapy To Enhance Efficacy By Mobilizing AML Cancer Cells From Bone Marrow